


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. - 137. (cancelled)

138. (new) A pharmaceutical or cosmetic composition comprising at least one of a pharmaceutically or cosmetically acceptable carrier and a pharmaceutically or cosmetically acceptable adjuvant and at least one active ingredient selected from a compound of formula:



and pharmaceutically acceptable salts thereof.

139. (new) A method of inhibiting an activity of at least one enzyme selected from alanyl aminopeptidases, dipeptidyl peptidase and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject the composition of claim 138 in an amount sufficient for inhibiting the activity of the at least one enzyme.

140. (new) A method of preventing or treating at least one condition selected from multiple sclerosis, Morbus Crohn, Colitis ulcerosa, rheumatoid arthritis, diabetes type I, autoimmune thyroid gland diseases, Morbus Wegener, systemic Lupus erythematosus visceralis and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale, allergic rhinitis, food allergy, atopic eczema, contact dermatitis, urticaria, angioedema and other allergic diseases; rejection of allogenic or xenogenic transplanted organs, tissues and cells such as, e.g. kidney, heart, liver, pancreas, skin or stem cell transplants; graft-versus-host diseases; skin and mucosa diseases; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts; acute neuronal diseases, in particular ischemia-caused cerebral damages after an ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Alzheimer's disease, Pick's disease, Progressive Supranuclear Palsy, cortical degeneration, frontotemporal dementia, Parkinson's disease, Huntington's disease, prion-caused diseases and amyotrophic lateral sclerosis; chronic obstructive pulmonal diseases (COPD); prostata carcinoma and other tumors as well as metastases; Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-like conditions in a subject in need thereof, wherein the method comprises administering to the subject the composition of claim 138 in an amount sufficient for preventing or treating the at least one condition.

141. (new) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, reperfusion syndrome and stent restenosis in a subject in need

thereof, wherein the method comprises administering to the subject the composition of claim 138 in an amount sufficient for preventing or treating the at least one condition.

142. (new) The method of claim 141, wherein the method comprises administering the composition by using a stent which is coated with the at least one of a composition and an active ingredient thereof.

143. (new) A method of preventing or treating an inflammation reaction at, or caused by, a medical device implanted into an organism, wherein the method comprises administering to the organism the composition of claim 138 in an amount sufficient for preventing or treating the inflammation reaction.

144. (new) The method of claim 143, wherein the method comprises administering the composition at least one of as a coating or layer on the medical device and incorporated in the medical device.

145. (new) The method of claim 143, wherein the method comprises administering the composition by at least one of a local and a systemic administration successively or concurrently.